Total Payments
$261,905
2024 Payments
$906.52
Companies
52
Transactions
391
Medicare Patients
12,592
Medicare Billing
$3.1M
Payment Breakdown by Category
Other$137,889 (52.6%)
Consulting$91,357 (34.9%)
Travel$22,009 (8.4%)
Food & Beverage$8,024 (3.1%)
Research$2,284 (0.9%)
Education$341.98 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $122,386 | 41 | 46.7% |
| Consulting Fee | $91,357 | 28 | 34.9% |
| Travel and Lodging | $22,009 | 67 | 8.4% |
| Honoraria | $15,503 | 7 | 5.9% |
| Food and Beverage | $8,024 | 232 | 3.1% |
| Unspecified | $2,284 | 7 | 0.9% |
| Education | $341.98 | 9 | 0.1% |
Payments by Type
General
$259,621
384 transactions
Research
$2,284
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kite Pharma, Inc. | $132,520 | 100 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $41,223 | 59 | $0 (2024) |
| Celgene Corporation | $17,879 | 18 | $0 (2023) |
| Dova Pharmaceuticals | $17,251 | 11 | $0 (2021) |
| Karyopharm Therapeutics Inc. | $15,722 | 15 | $0 (2024) |
| Seattle Genetics, Inc. | $9,622 | 8 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $9,460 | 14 | $0 (2018) |
| Gilead Sciences, Inc. | $4,406 | 11 | $0 (2021) |
| Genentech USA, Inc. | $3,378 | 4 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $3,098 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $906.52 | 38 | Kite Pharma, Inc. ($98.28) |
| 2023 | $1,746 | 62 | Janssen Biotech, Inc. ($224.11) |
| 2022 | $27,126 | 27 | Kite Pharma, Inc. ($26,709) |
| 2021 | $41,606 | 51 | Kite Pharma, Inc. ($23,055) |
| 2020 | $53,102 | 47 | Kite Pharma, Inc. ($29,717) |
| 2019 | $55,521 | 67 | Rigel Pharmaceuticals, Inc. ($19,793) |
| 2018 | $76,869 | 77 | Kite Pharma, Inc. ($40,605) |
| 2017 | $5,027 | 22 | Bayer HealthCare Pharmaceuticals Inc. ($4,712) |
All Payment Transactions
391 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/17/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: Oncology | ||||||
| 08/05/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $62.94 | General |
| Category: CELLT | ||||||
| 08/05/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2024 | GENZYME CORPORATION | ENJAYMO (Biological), CABLIVI | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: Hematology | ||||||
| 05/13/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $23.41 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 05/09/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $28.91 | General |
| Category: Oncology | ||||||
| 05/03/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: Oncology | ||||||
| 05/03/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $20.79 | General |
| 04/11/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $21.36 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 04/11/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $2.24 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 04/10/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $25.22 | General |
| 03/25/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $27.69 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/19/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: HEMATOLOGY | ||||||
| 03/14/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $21.26 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/14/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.27 | General |
| Category: Hematology/Oncology | ||||||
| 03/08/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: ONCOLOGY | ||||||
| 03/07/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: Oncology | ||||||
| 03/04/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $31.05 | General |
| Category: Oncology | ||||||
| 03/01/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $28.66 | General |
| Category: ONCOLOGY | ||||||
| 02/21/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: Oncology | ||||||
| 02/19/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: HEMATOLOGY | ||||||
| 02/17/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: ONCOLOGY | ||||||
| 02/15/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $25.14 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| C-935788-057 | Rigel Pharmaceuticals, Inc. | $2,175 | 6 |
| A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA 2) | Kite Pharma, Inc. | $108.81 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 52 | 2,706 | 39,091 | $2.7M | $662,664 |
| 2022 | 67 | 3,243 | 61,656 | $3.6M | $791,873 |
| 2021 | 61 | 3,526 | 63,540 | $3.8M | $889,457 |
| 2020 | 53 | 3,117 | 42,002 | $3.0M | $792,114 |
Total Patients
12,592
Total Services
206,289
Medicare Billing
$3.1M
Procedure Codes
233
All Medicare Procedures & Services
233 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 30 | 8,400 | $1.2M | $364,899 | 31.6% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 12 | 2,880 | $363,240 | $108,561 | 29.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 176 | 510 | $187,680 | $47,399 | 25.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 140 | 198 | $139,986 | $20,702 | 14.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 60 | 123 | $61,008 | $16,757 | 27.5% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 11 | 14 | $67,228 | $15,346 | 22.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 214 | 718 | $45,952 | $7,427 | 16.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 213 | 859 | $17,180 | $7,207 | 42.0% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 35 | 37 | $39,479 | $6,678 | 16.9% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 48 | 338 | $20,280 | $5,721 | 28.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 95 | 228 | $35,796 | $5,255 | 14.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 194 | 676 | $24,336 | $5,144 | 21.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 72 | $17,784 | $4,482 | 25.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 46 | $16,422 | $4,307 | 26.2% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 35 | 113 | $16,159 | $3,958 | 24.5% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 46 | 63 | $21,672 | $3,248 | 15.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 43 | 52 | $13,000 | $2,773 | 21.3% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 175 | 436 | $13,516 | $2,578 | 19.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $9,605 | $2,161 | 22.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 42 | 44 | $13,772 | $2,139 | 15.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $10,635 | $2,055 | 19.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 91 | 162 | $17,496 | $2,001 | 11.4% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 38 | 40 | $32,840 | $2,000 | 6.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 18 | 30 | $6,330 | $1,749 | 27.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $8,328 | $1,638 | 19.7% |
About Dr. Houston Holmes, M.D
Dr. Houston Holmes, M.D is a Hematology & Oncology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053354464.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Houston Holmes, M.D has received a total of $261,905 in payments from pharmaceutical and medical device companies, with $906.52 received in 2024. These payments were reported across 391 transactions from 52 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($122,386).
As a Medicare-enrolled provider, Holmes has provided services to 12,592 Medicare beneficiaries, totaling 206,289 services with total Medicare billing of $3.1M. Data is available for 4 years (2020–2023), covering 233 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Dallas, TX
- Active Since 06/14/2006
- Last Updated 06/14/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1053354464
Products in Payments
- Yescarta (Drug) $105,112
- Tavalisse (Drug) $36,511
- Doptelet (Drug) $17,278
- XPOVIO (Drug) $15,722
- Tecartus (Drug) $13,520
- ADCETRIS (Biological) $9,668
- Aliqopa (Drug) $4,748
- Non-Covered $4,712
- Revlimid (Drug) $3,504
- Rituxan (Biological) $3,345
- DARZALEX (Biological) $1,609
- CALQUENCE (Drug) $992.26
- Non-Covered Product (Drug) $346.35
- Rezlidhia (Drug) $212.09
- IMBRUVICA (Drug) $148.50
- JAKAFI (Drug) $142.59
- TAZVERIK (Drug) $138.14
- SARCLISA (Biological) $127.00
- MONJUVI (Drug) $123.93
- Epkinly (Drug) $110.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Dallas
Dr. Christopher Maisel, Md, MD
Hematology & Oncology — Payments: $884,793
Hematology & Oncology $884,793
Dr. Kartik Konduri, Md, MD
Hematology & Oncology — Payments: $253,193
Hematology & Oncology $253,193
Dr. Farrukh Awan, M.d., M.s, M.D., M.S
Hematology & Oncology — Payments: $184,107
Hematology & Oncology $184,107
Dr. Joanne Blum, M.d, M.D
Hematology & Oncology — Payments: $183,987
Hematology & Oncology $183,987
Joan Schiller, Md, MD
Hematology & Oncology — Payments: $174,115
Hematology & Oncology $174,115
Dr. Carlos Becerra, M.d, M.D
Hematology & Oncology — Payments: $161,287
Hematology & Oncology $161,287